Novel Therapeutics for Immunological Diseases
Developing safer, more durable treatments to improve the lives of patients
More

ALTB-168 Neihulizumab
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase II Phase 2a Psoriatic Arthritis trial completed with proof of clinical efficacy achieved.
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase II Phase 2a anti-TNF α and/or anti-integrin refractory/intolerant Ulcerative Colitis trial completed with proof of clinical efficacy achieved; continued UC development planned with ALTB-268.
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase I Phase 1b multi-dose steroid refractory acute graft versus host disease trial ongoing
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase I Investigator sponsored Phase 1 front line acute graft versus host disease trial ongoing.
ALTB-268
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Preclinical Potency improved version of ALTB-168 for Chronic Inflammatory Disease
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Preclinical Renal Transplantation Non-Human Primate preclinical studies ongoing.
2F.,No. 36, Ln. 358, Ruiguang Rd.,
Neihu, Taipei, Taiwan 114063
Tel: (886)-2-2627-2707
E-mail: info@altrubio.com
505 Montgomery Street, 11th Floor
San Francisco, CA 94111 U.S.A.
Tel: (415)655-6618
E-mail: info@altrubio.com